Category: Uncategorized

Making brain implants smaller could prolong their lifespan

Anne Trafton |

Many diseases, including Parkinson’s disease, can be treated with electrical stimulation from an electrode implanted in the brain. However, the electrodes can produce scarring, which diminishes their effectiveness and can necessitate additional surgeries to replace them.

MIT researchers have now demonstrated that making these electrodes much smaller can essentially eliminate this scarring, potentially allowing the devices to remain in the brain for much longer.

“What we’re doing is changing the scale and making the procedure less invasive,” says Michael Cima, the David H. Koch Professor of Engineering in the Department of Materials Science and Engineering, a member of MIT’s Koch Institute for Integrative Cancer Research, and the senior author of the study, which appears in the May 16 issue of Scientific Reports.

Cima and his colleagues are now designing brain implants that can not only deliver electrical stimulation but also record brain activity or deliver drugs to very targeted locations.

The paper’s lead author is former MIT graduate student Kevin Spencer. Other authors are former postdoc Jay Sy, graduate student Khalil Ramadi, Institute Professor Ann Graybiel, and David H. Koch Institute Professor Robert Langer.

Effects of size

Many Parkinson’s patients have benefited from treatment with low-frequency electrical current delivered to a part of the brain involved in movement control. The electrodes used for this deep brain stimulation are a few millimeters in diameter. After being implanted, they gradually generate scar tissue through the constant rubbing of the electrode against the surrounding brain tissue. This process, known as gliosis, contributes to the high failure rate of such devices: About half stop working within the first six months.

Previous studies have suggested that making the implants smaller or softer could reduce the amount of scarring, so the MIT team set out to measure the effects of both reducing the size of the implants and coating them with a soft polyethylene glycol (PEG) hydrogel.

The hydrogel coating was designed to have an elasticity very similar to that of the brain. The researchers could also control the thickness of the coating. They found that when coated electrodes were pushed into the brain, the soft coating would fall off, so they devised a way to apply the hydrogel and then dry it, so that it becomes a hard, thin film. After the electrode is inserted, the film soaks up water and becomes soft again.

In mice, the researchers tested both coated and uncoated glass fibers with varying diameters and found that there is a tradeoff between size and softness. Coated fibers produced much less scarring than uncoated fibers of the same diameter. However, as the electrode fibers became smaller, down to about 30 microns (0.03 millimeters) in diameter, the uncoated versions produced less scarring, because the coatings increase the diameter.

This suggests that a 30-micron, uncoated fiber is the optimal design for implantable devices in the brain.

“Before this paper, no one really knew the effects of size,” Cima says. “Softer is better, but not if it makes the electrode larger.”

New devices

The question now is whether fibers that are only 30 microns in diameter can be adapted for electrical stimulation, drug delivery, and recording electrical activity in the brain. Cima and his colleagues have had some initial success developing such devices.

“It’s one of those things that at first glance seems impossible. If you have 30-micron glass fibers, that’s slightly thicker than a piece of hair. But it is possible to do,” Cima says.
Such devices could be potentially useful for treating Parkinson’s disease or other neurological disorders. They could also be used to remove fluid from the brain to monitor whether treatments are having the intended effect, or to measure brain activity that might indicate when an epileptic seizure is about to occur.

The research was funded by the National Institutes of Health and MIT’s Institute for Soldier Nanotechnologies.

High-resolution imaging with conventional microscopes

Anne Trafton |

MIT researchers have developed a way to make extremely high-resolution images of tissue samples, at a fraction of the cost of other techniques that offer similar resolution.

The new technique relies on expanding tissue before imaging it with a conventional light microscope. Two years ago, the MIT team showed that it was possible to expand tissue volumes 100-fold, resulting in an image resolution of about 60 nanometers. Now, the researchers have shown that expanding the tissue a second time before imaging can boost the resolution to about 25 nanometers.

This level of resolution allows scientists to see, for example, the proteins that cluster together in complex patterns at brain synapses, helping neurons to communicate with each other. It could also help researchers to map neural circuits, says Ed Boyden, an associate professor of biological engineering and brain and cognitive sciences at MIT.

“We want to be able to trace the wiring of complete brain circuits,” says Boyden, the study’s senior author. “If you could reconstruct a complete brain circuit, maybe you could make a computational model of how it generates complex phenomena like decisions and emotions. Since you can map out the biomolecules that generate electrical pulses within cells and that exchange chemicals between cells, you could potentially model the dynamics of the brain.”

This approach could also be used to image other phenomena such as the interactions between cancer cells and immune cells, to detect pathogens without expensive equipment, and to map the cell types of the body.

Former MIT postdoc Jae-Byum Chang is the first author of the paper, which appears in the April 17 issue of Nature Methods.

Double expansion

To expand tissue samples, the researchers embed them in a dense, evenly generated gel made of polyacrylate, a very absorbent material that’s also used in diapers. Before the gel is formed, the researchers label the cell proteins they want to image, using antibodies that bind to specific targets. These antibodies bear “barcodes” made of DNA, which in turn are attached to cross-linking molecules that bind to the polymers that make up the expandable gel. The researchers then break down the proteins that normally hold the tissue together, allowing the DNA barcodes to expand away from each other as the gel swells.

These enlarged samples can then be labeled with fluorescent probes that bind the DNA barcodes, and imaged with commercially available confocal microscopes, whose resolution is usually limited to hundreds of nanometers.

Using that approach, the researchers were previously able to achieve a resolution of about 60 nanometers. However, “individual biomolecules are much smaller than that, say 5 nanometers or even smaller,” Boyden says. “The original versions of expansion microscopy were useful for many scientific questions but couldn’t equal the performance of the highest-resolution imaging methods such as electron microscopy.”

In their original expansion microscopy study, the researchers found that they could expand the tissue more than 100-fold in volume by reducing the number of cross-linking molecules that hold the polymer in an orderly pattern. However, this made the tissue unstable.

“If you reduce the cross-linker density, the polymers no longer retain their organization during the expansion process,” says Boyden, who is a member of MIT’s Media Lab and McGovern Institute for Brain Research. “You lose the information.”

Instead, in their latest study, the researchers modified their technique so that after the first tissue expansion, they can create a new gel that swells the tissue a second time — an approach they call “iterative expansion.”

Mapping circuits

Using iterative expansion, the researchers were able to image tissues with a resolution of about 25 nanometers, which is similar to that achieved by high-resolution techniques such as stochastic optical reconstruction microscopy (STORM). However, expansion microscopy is much cheaper and simpler to perform because no specialized equipment or chemicals are required, Boyden says. The method is also much faster and thus compatible with large-scale, 3-D imaging.

The resolution of expansion microscopy does not yet match that of scanning electron microscopy (about 5 nanometers) or transmission electron microscopy (about 1 nanometer). However, electron microscopes are very expensive and not widely available, and with those microscopes, it is difficult for researchers to label specific proteins.

In the Nature Methods paper, the MIT team used iterative expansion to image synapses — the connections between neurons that allow them to communicate with each other. In their original expansion microscopy study, the researchers were able to image scaffolding proteins, which help to organize the hundreds of other proteins found in synapses. With the new, enhanced resolution, the researchers were also able to see finer-scale structures, such as the location of neurotransmitter receptors located on the surfaces of the “postsynaptic” cells on the receiving side of the synapse.

“My hope is that we can, in the coming years, really start to map out the organization of these scaffolding and signaling proteins at the synapse,” Boyden says.

Combining expansion microscopy with a new tool called temporal multiplexing should help to achieve that, he believes. Currently, only a limited number of colored probes can be used to image different molecules in a tissue sample. With temporal multiplexing, researchers can label one molecule with a fluorescent probe, take an image, and then wash the probe away. This can then be repeated many times, each time using the same colors to label different molecules.

“By combining iterative expansion with temporal multiplexing, we could in principle have essentially infinite-color, nanoscale-resolution imaging over large 3-D volumes,” Boyden says. “Things are getting really exciting now that these different technologies may soon connect with each other.”

The researchers also hope to achieve a third round of expansion, which they believe could, in principle, enable resolution of about 5 nanometers. However, right now the resolution is limited by the size of the antibodies used to label molecules in the cell. These antibodies are about 10 to 20 nanometers long, so to get resolution below that, researchers would need to create smaller tags or expand the proteins away from each other first and then deliver the antibodies after expansion.

This study was funded by the National Institutes of Health Director’s Pioneer Award, the New York Stem Cell Foundation Robertson Award, the HHMI-Simons Faculty Scholars Award, and the Open Philanthropy Project.

Scientists unveil CRISPR-based diagnostic platform

Anne Trafton |

A team of scientists from the Broad Institute of MIT and Harvard, the McGovern Institute for Brain Research at MIT, the Institute for Medical Engineering and Science at MIT, and the Wyss Institute for Biologically Inspired Engineering at Harvard University has adapted a CRISPR protein that targets RNA (rather than DNA), for use as a rapid, inexpensive, highly sensitive diagnostic tool with the potential to transform research and global public health.

In a study published today in Science, Broad Institute members Feng Zhang, Jim Collins, Deb Hung, Aviv Regev, and Pardis Sabeti describe how this RNA-targeting CRISPR enzyme was harnessed as a highly sensitive detector — able to indicate the presence of as little as a single molecule of a target RNA or DNA. Co-first authors Omar Abudayyeh and Jonathan Gootenberg, graduate students at MIT and Harvard, respectively, dubbed the new tool SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing); this technology could one day be used to respond to viral and bacterial outbreaks, monitor antibiotic resistance, and detect cancer.

The scientists demonstrate the method’s versatility on a range of applications, including:

• detecting the presence of Zika virus in patient blood or urine samples within hours;
• distinguishing between the genetic sequences of African and American strains of Zika virus;
• discriminating specific types of bacteria, such as E. coli;
• detecting antibiotic resistance genes;
• identifying cancerous mutations in simulated cell-free DNA fragments; and
• rapidly reading human genetic information, such as risk of heart disease, from a saliva sample.

Because the tool can be designed for use as a paper-based test that does not require refrigeration, the researchers say it is well-suited for fast deployment and widespread use inside and outside of traditional settings — such as at a field hospital during an outbreak, or a rural clinic with limited access to advanced equipment.

“It’s exciting that the Cas13a enzyme, which was originally identified in our collaboration with Eugene Koonin to study the basic biology of bacterial immunity, can be harnessed to achieve such extraordinary sensitivity, which will be powerful for both science and clinical medicine,” says Feng Zhang, core institute member of the Broad Institute, an investigator at the McGovern Institute, and the James and Patricia Poitras ’63 Professor in Neuroscience and associate professor in the departments of Brain and Cognitive Sciences and Biological Engineering at MIT.

In June 2016, Zhang and his colleagues first characterized the RNA-targeting CRISPR enzyme, now called Cas13a (previously known as C2c2), which can be programmed to cleave particular RNA sequences in bacterial cells. Unlike DNA-targeting CRISPR enzymes (such as Cas9 and Cpf1), Cas13a can remain active after cutting its intended RNA target and may continue to cut other nontargeted RNAs in a burst of activity that Zhang lab scientists referred to as “collateral cleavage.” In their paper and patent filing, the team described a wide range of biotechnological applications for the system, including harnessing RNA cleavage and collateral activity for basic research, diagnostics, and therapeutics.

In a paper in Nature in September 2016, Jennifer Doudna, Alexandra East-Seletsky, and their colleagues at the University of California at Berkeley employed the Cas13a collateral cleavage activity for RNA detection. That method required the presence of many millions of molecules, however, and therefore lacked the sensitivity required for many research and clinical applications.

The method reported today is a million-fold more sensitive. This increase was the result of a collaboration between Zhang and his team and Broad Institute member Jim Collins, who had been working on diagnostics for Zika virus.

Working together, the Zhang and Collins teams were able to use a different amplification process, relying on body heat, to boost the levels of DNA or RNA in their test samples. Once the level was increased, the team applied a second amplification step to convert the DNA to RNA, which enabled them to increase the sensitivity of the RNA-targeting CRISPR by a millionfold, all with a tool that can be used in nearly any setting.

“We can now effectively and readily make sensors for any nucleic acid, which is incredibly powerful when you think of diagnostics and research applications,” says Collins, the Termeer Professor of Medical Engineering and Science at MIT and core faculty member at the Wyss Institute. “This tool offers the sensitivity that could detect an extremely small amount of cancer DNA in a patient’s blood sample, for example, which would help researchers understand how cancer mutates over time. For public health, it could help researchers monitor the frequency of antibiotic-resistant bacteria in a population. The scientific possibilities get very exciting very quickly.”

One of the most urgent and obvious applications for this new diagnostic tool would be as a rapid, point-of-care diagnostic for infectious disease outbreaks in resource-poor areas.
“There is great excitement around this system,” says Deb Hung, co-author and co-director of the Broad’s Infectious Disease and Microbiome Program. “There is still much work to be done, but if SHERLOCK can be developed to its full potential it could fundamentally change the diagnosis of common and emerging infectious diseases.”

“One thing that’s especially powerful about SHERLOCK is its ability to start testing without a lot of complicated and time-consuming upstream experimental work,” says Pardis Sabeti, also a co-author in the paper. In the wake of the ongoing Zika outbreak, Sabeti and the members of her lab have been working to collect samples, rapidly sequence genomes, and share data in order to accelerate the outbreak response effort. “This ability to take raw samples and immediately start processing could transform the diagnosis of Zika and a boundless number of other infectious diseases,” she says. “This is just the beginning.”

Additional authors include Jeong Wook Lee, Patrick Essletzbichler, Aaron J. Dy, Julia Joung, Vanessa Verdine, Nina Donghia, Nichole M. Daringer, Catherine A. Freije, Cameron Myhrvold, Roby P. Bhattacharyya, Jonathan Livny, and Eugene V. Koonin.

2017 Sharp Lecture: Larry Abbott

Anne Trafton |

March 20, 2017
Phillip A. Sharp Lecture in Neural Circuits
Sponsored by Biogen Idec

“Unmarring the Perceptron: Lessons in Cerebellar Computing from Fish and Flies”
Larry Abbott, Columbia University

Precise technique tracks dopamine in the brain

Anne Trafton |

MIT researchers have devised a way to measure dopamine in the brain much more precisely than previously possible, which should allow scientists to gain insight into dopamine’s roles in learning, memory, and emotion.

Dopamine is one of the many neurotransmitters that neurons in the brain use to communicate with each other. Previous systems for measuring these neurotransmitters have been limited in how long they provide accurate readings and how much of the brain they can cover. The new MIT device, an array of tiny carbon electrodes, overcomes both of those obstacles.

“Nobody has really measured neurotransmitter behavior at this spatial scale and timescale. Having a tool like this will allow us to explore potentially any neurotransmitter-related disease,” says Michael Cima, the David H. Koch Professor of Engineering in the Department of Materials Science and Engineering, a member of MIT’s Koch Institute for Integrative Cancer Research, and the senior author of the study.

Furthermore, because the array is so tiny, it has the potential to eventually be adapted for use in humans, to monitor whether therapies aimed at boosting dopamine levels are succeeding. Many human brain disorders, most notably Parkinson’s disease, are linked to dysregulation of dopamine.

“Right now deep brain stimulation is being used to treat Parkinson’s disease, and we assume that that stimulation is somehow resupplying the brain with dopamine, but no one’s really measured that,” says Helen Schwerdt, a Koch Institute postdoc and the lead author of the paper, which appears in the journal Lab on a Chip.

Studying the striatum

For this project, Cima’s lab teamed up with David H. Koch Institute Professor Robert Langer, who has a long history of drug delivery research, and Institute Professor Ann Graybiel, who has been studying dopamine’s role in the brain for decades with a particular focus on a brain region called the striatum. Dopamine-producing cells within the striatum are critical for habit formation and reward-reinforced learning.

Until now, neuroscientists have used carbon electrodes with a shaft diameter of about 100 microns to measure dopamine in the brain. However, these can only be used reliably for about a day because they produce scar tissue that interferes with the electrodes’ ability to interact with dopamine, and other types of interfering films can also form on the electrode surface over time. Furthermore, there is only about a 50 percent chance that a single electrode will end up in a spot where there is any measurable dopamine, Schwerdt says.

The MIT team designed electrodes that are only 10 microns in diameter and combined them into arrays of eight electrodes. These delicate electrodes are then wrapped in a rigid polymer called PEG, which protects them and keeps them from deflecting as they enter the brain tissue. However, the PEG is dissolved during the insertion so it does not enter the brain.

These tiny electrodes measure dopamine in the same way that the larger versions do. The researchers apply an oscillating voltage through the electrodes, and when the voltage is at a certain point, any dopamine in the vicinity undergoes an electrochemical reaction that produces a measurable electric current. Using this technique, dopamine’s presence can be monitored at millisecond timescales.

Using these arrays, the researchers demonstrated that they could monitor dopamine levels in many parts of the striatum at once.

“What motivated us to pursue this high-density array was the fact that now we have a better chance to measure dopamine in the striatum, because now we have eight or 16 probes in the striatum, rather than just one,” Schwerdt says.

The researchers found that dopamine levels vary greatly across the striatum. This was not surprising, because they did not expect the entire region to be continuously bathed in dopamine, but this variation has been difficult to demonstrate because previous methods measured only one area at a time.

How learning happens

The researchers are now conducting tests to see how long these electrodes can continue giving a measurable signal, and so far the device has kept working for up to two months. With this kind of long-term sensing, scientists should be able to track dopamine changes over long periods of time, as habits are formed or new skills are learned.

“We and other people have struggled with getting good long-term readings,” says Graybiel, who is a member of MIT’s McGovern Institute for Brain Research. “We need to be able to find out what happens to dopamine in mouse models of brain disorders, for example, or what happens to dopamine when animals learn something.”

She also hopes to learn more about the roles of structures in the striatum known as striosomes. These clusters of cells, discovered by Graybiel many years ago, are distributed throughout the striatum. Recent work from her lab suggests that striosomes are involved in making decisions that induce anxiety.

This study is part of a larger collaboration between Cima’s and Graybiel’s labs that also includes efforts to develop injectable drug-delivery devices to treat brain disorders.

“What links all these studies together is we’re trying to find a way to chemically interface with the brain,” Schwerdt says. “If we can communicate chemically with the brain, it makes our treatment or our measurement a lot more focused and selective, and we can better understand what’s going on.”

Other authors of the paper are McGovern Institute research scientists Minjung Kim, Satoko Amemori, and Hideki Shimazu; McGovern Institute postdoc Daigo Homma; McGovern Institute technical associate Tomoko Yoshida; and undergraduates Harshita Yerramreddy and Ekin Karasan.

The research was funded by the National Institutes of Health, the National Institute of Biomedical Imaging and Bioengineering, and the National Institute of Neurological Disorders and Stroke.

McGovern Institute awards 2017 Scolnick Prize to Catherine Dulac

by Charles Jennings |

The McGovern Institute for Brain Research at MIT announced today that Catherine Dulac of Harvard University is the winner of the 2017 Edward M. Scolnick Prize in Neuroscience. She was awarded the prize for her contributions to the understanding of how pheromones control brain function and behavior and the characterization of neuronal circuits underlying sex-specific behaviors. The Scolnick Prize is awarded annually by the McGovern Institute to recognize outstanding advances in any field of neuroscience.

Dulac is the Higgins Professor in the Department of Molecular and Cellular Biology at Harvard University, where she served as Department Chair from 2007-2013. She is also an investigator of the Howard Hughes Medical Institute. She received her PhD from Pierre and Marie Curie University in Paris, where she studied mechanisms of neural crest development with Nicole le Douarin at the College de France. She moved to the US in 1992 as a postdoctoral fellow in the laboratory of Richard Axel at Columbia University, and joined the Harvard faculty in 1996.

Catherine DulacDulac is best known for her discovery of pheromone receptors and downstream brain circuits controlling sex-specific behaviors. Pheromones are volatile chemical signals that play a major role in controlling mammalian behaviors, in particular social and sexual behaviors such as aggression and reproduction. Unlike odorants, which give rise to the perception of smell, and which can be learned and flexibly associated with different stimuli, the responses to pheromones are fixed and stereotypic. Pheromone responses were known to require the vomeronasal organ (VNO), a specialized part of the olfactory epithelium within the nose, but until Dulac’s work, the molecular identity of the receptors and the neuronal circuits that underlie pheromone-evoked responses had been elusive.

In work that began while she was a postdoc, Dulac set out to identify these receptors, developing novel methods for analyzing RNA from individual sensory neurons. This pioneering work not only led her to the discovery of a large family of pheromone receptor genes, but also demonstrated the feasibility of analyzing the transcriptomes of individual neurons, an approach that is now widely used to study the brain’s extraordinary complexity.

Soon after starting her own lab at Harvard, Dulac discovered a second family of pheromone receptors. Both families are distinct from odorant receptors and are expressed in characteristic spatial patterns within the VNO. Dulac went on to study the mechanism of pheromone action, identifying the ion channel TRPC2 as an essential player in the response of VNO neurons to pheromone signaling. By genetically manipulating this signaling pathway in mice, Dulac was able to show that inputs from the VNO are necessary for gender identification and for the sex-specificity of social behaviors, including mating, aggression and parenting. She was also able to trace the connections from the VNO to the brain systems that control these behaviors, and to characterize specific neuronal populations that are necessary and sufficient for specific social behaviors. In one study, for example, she identified a population of neurons within the hypothalamus that induce parenting behaviors while suppressing aggression toward the offspring that would otherwise be triggered in males by signals from the VNO.

In another recent line of work, Dulac has studied genomic imprinting, an epigenetic phenomenon by which certain genes are differentially expressed depending on whether they were inherited from the mother or the father. Dulac’s work has revealed that imprinting of brain genes is much more common than previously realized, with important implications for basic biology and for the epidemiology of brain disorders.
Among her many honors and awards, Dulac is a fellow of the American Academy of Arts and Sciences, a Chevalier de la Legion d’Honneur, a member of the French Academy of Sciences, and a member of the US National Academy of Sciences.

The McGovern Institute will award the Scolnick Prize to Dr. Dulac on Monday March 13. At 4:00pm she will deliver a lecture entitled “The Neurobiology of Social Behavior Circuits,” to be followed by a reception, at the McGovern Institute in the Brain and Cognitive Sciences Complex, 43 Vassar Street (building 46, room 3002) in Cambridge. The event is free and open to the public.

New center for autism research established at the McGovern Institute

by McGovern Institute |

The McGovern Institute is pleased to announce the establishment of a new center dedicated to autism research. The center is made possible by a kick-off commitment of $20 million, made by Lisa Yang and MIT alumnus Hock Tan ’75.

The Hock E. Tan and K. Lisa Yang Center for Autism Research will support research on the genetic, biological and neural bases of autism spectrum disorders, a developmental disability estimated to affect 1 in 68 individuals in the United States. Tan and Yang hope their initial investment will stimulate additional support and help foster collaborative research efforts to erase the devastating effects of this disorder on individuals, their families and the broader autism community.

“With the Tan-Yang Center for Autism Research, we can imagine a world in which medical science understands and supports those with autism — and we can focus MIT’s distinctive strengths on making that dream a reality. Lisa and Hock’s gift reminds us of the impact we envision for the MIT Campaign for a Better World.  I am grateful for their leadership and generosity, and inspired by the possibilities ahead,” says MIT President L. Rafael Reif.

“I am thrilled to be investing in an institution that values a multidisciplinary collaborative approach to solving complex problems such as autism,” says Hock Tan, who graduated from MIT in 1975 with a bachelor’s degree and master’s degree in mechanical engineering. “We expect that successful research originating from our Center will have a significant impact on the autism community.”

Originally from Penang, Malaysia, Tan has held several high-level finance and executive positions since leaving MIT. Tan is currently CEO of chipmaker Broadcom, Ltd.

Research at the Tan-Yang Center will focus on four major lines of investigation: genetics, neural circuits, novel autism models and the translation of basic research to the clinical setting.  By focusing research efforts on the origins of autism in our genes, in the womb and in the first years of life, the Tan-Yang Center aims to develop methods to better detect and potentially prevent autism spectrum disorders entirely. To help meet this challenge, the Center will support collaborations across multiple disciplines—from genes to neural circuits—both within and beyond MIT.

“MIT has some of the world’s leading scientists studying autism,” says McGovern Institute director Robert Desimone. “Support from the Tan-Yang Center will enable us to pursue exciting new directions that could not be funded by traditional sources. We will exploit revolutionary new tools, such as CRISPR and optogenetics, that are transforming research in neuroscience. We hope to not only identify new targets for medicines, but also develop novel treatments that are not based on standard pharmacological approaches. By supporting cutting-edge autism research here at MIT as well as our collaborative institutions, the Center holds great promise to accelerate our basic understanding of this complex disorder.”

“Millions of families have been impacted by autism,” says Yang, a longtime advocate for the rights of individuals with disabilities and learning differences. “I am profoundly hopeful that the discoveries made at the Tan-Yang Center will have a long-term impact on the field of autism research and will provide fresh answers and potential new treatments for individuals affected by this disorder.”

Sensor traces dopamine released by single cells

Anne Trafton |

MIT chemical engineers have developed an extremely sensitive detector that can track single cells’ secretion of dopamine, a brain chemical responsible for carrying messages involved in reward-motivated behavior, learning, and memory.

Using arrays of up to 20,000 tiny sensors, the researchers can monitor dopamine secretion of single neurons, allowing them to explore critical questions about dopamine dynamics. Until now, that has been very difficult to do.

“Now, in real-time, and with good spatial resolution, we can see exactly where dopamine is being released,” says Michael Strano, the Carbon P. Dubbs Professor of Chemical Engineering and the senior author of a paper describing the research, which appears in the Proceedings of the National Academy of Sciences the week of Feb. 6.

Strano and his colleagues have already demonstrated that dopamine release occurs differently than scientists expected in a type of neural progenitor cell, helping to shed light on how dopamine may exert its effects in the brain.

The paper’s lead author is Sebastian Kruss, a former MIT postdoc who is now at Göttingen University, in Germany. Other authors are Daniel Salem and Barbara Lima, both MIT graduate students; Edward Boyden, an associate professor of biological engineering and brain and cognitive sciences, as well as a member of the MIT Media Lab and the McGovern Institute for Brain Research; Lela Vukovic, an assistant professor of chemistry at the University of Texas at El Paso; and Emma Vander Ende, a graduate student at Northwestern University.

“A global effect”

Dopamine is a neurotransmitter that plays important roles in learning, memory, and feelings of reward, which reinforce positive experiences.

Neurotransmitters allow neurons to relay messages to nearby neurons through connections known as synapses. However, unlike most other neurotransmitters, dopamine can exert its effects beyond the synapse: Not all dopamine released into a synapse is taken up by the target cell, allowing some of the chemical to diffuse away and affect other nearby cells.

“It has a local effect, which controls the signaling through the neurons, but also it has a global effect,” Strano says. “If dopamine is in the region, it influences all the neurons nearby.”

Tracking this dopamine diffusion in the brain has proven difficult. Neuroscientists have tried using electrodes that are specialized to detect dopamine, but even using the smallest electrodes available, they can place only about 20 near any given cell.

“We’re at the infancy of really understanding how these packets of chemicals move and their directionality,” says Strano, who decided to take a different approach.

Strano’s lab has previously developed sensors made from arrays of carbon nanotubes — hollow, nanometer-thick cylinders made of carbon, which naturally fluoresce when exposed to laser light. By wrapping these tubes in different proteins or DNA strands, scientists can customize them to bind to different types of molecules.

The carbon nanotube sensors used in this study are coated with a DNA sequence that makes the sensors interact with dopamine. When dopamine binds to the carbon nanotubes, they fluoresce more brightly, allowing the researchers to see exactly where the dopamine was released. The researchers deposited more than 20,000 of these nanotubes on a glass slide, creating an array that detects any dopamine secreted by a cell placed on the slide.

Dopamine diffusion

In the new PNAS study, the researchers used these dopamine sensors to explore a longstanding question about dopamine release in the brain: From which part of the cell is dopamine secreted?

To help answer that question, the researchers placed individual neural progenitor cells known as PC-12 cells onto the sensor arrays. PC-12 cells, which develop into neuron-like cells under the right conditions, have a starfish-like shape with several protrusions that resemble axons, which form synapses with other cells.

After stimulating the cells to release dopamine, the researchers found that certain dopamine sensors near the cells lit up immediately, while those farther away turned on later as the dopamine diffused away. Tracking those patterns over many seconds allowed the researchers to trace how dopamine spreads away from the cells.

Strano says one might expect to see that most of the dopamine would be released from the tips of the arms extending out from the cells. However, the researchers found that in fact more dopamine came from the sides of the arms.

“We have falsified the notion that dopamine should only be released at these regions that will eventually become the synapses,” Strano says. “This observation is counterintuitive, and it’s a new piece of information you can only obtain with a nanosensor array like this one.”

The team also showed that most of the dopamine traveled away from the cell, through protrusions extending in opposite directions. “Even though dopamine is not necessarily being released only at the tip of these protrusions, the direction of release is associated with them,” Salem says.

Other questions that could be explored using these sensors include how dopamine release is affected by the direction of input to the cell, and how the presence of nearby cells influences each cell’s dopamine release.

The research was funded by the National Science Foundation, the National Institutes of Health, a University of Illinois Center for the Physics of Living Cells Postdoctoral Fellowship, the German Research Foundation, and a Liebig Fellowship.